Cyxone receives pre-IND response from the US FDA regarding RA study

Cyxone (publ), a biotech company in autoimmune diseases, has received a response from a Type B pre-IND meeting with the US Food and Drug Administration (FDA) regarding the upcoming study with the drug candidate Rabeximod, which is in development as a treatment for rheumatoid arthritis (RA).“We are pleased to now have received a written response from the pre-IND interaction we have had with the FDA and as expected they provided very valuable advice both regarding our preclinical and clinical development activities which ensure a continued adequate way forward for Rabeximod in RA. The FDA is